EUVIMEDEUVIMED entdecken
Crossref

A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma

Yetunde Ogunsesan, Ravi K. Shah, Mansi R. Shah, Meera Mohan

Advances in Oncology · 2026-05 · 6 (1) · 129-144

DOI: 10.1016/j.yao.2026.02.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Oncology, 2026-05. Verfasst von Yetunde Ogunsesan und 3 weiteren Autor:innen. Die Arbeit nennt 82 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Ogunsesan, Y., Shah, R. K., Shah, M. R., & Mohan, M. (2026). A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma. Advances in Oncology, 6(1), 129-144. https://doi.org/10.1016/j.yao.2026.02.003

Vancouver

Ogunsesan Y, Shah RK, Shah MR, Mohan M. A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma. Advances in Oncology. 2026;6(1):129-144. doi:10.1016/j.yao.2026.02.003

BibTeX
@article{Ogunsesan2026,
  author = {Ogunsesan, Yetunde and Shah, Ravi K. and Shah, Mansi R. and Mohan, Meera},
  title = {A Fixed-Duration Bispecific Antibody Strategy for Treatment of Multiple Myeloma},
  journal = {Advances in Oncology},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {129--144},
  doi = {10.1016/j.yao.2026.02.003}
}
Kostenlos starten →